HIT Consultant, a digital publication focused on healthcare technology, recently shared a report by Reed Smith on mergers and acquisitions (M&A) in life sciences and how personalized medicine is playing an important role in many of today’s transactions. While pharmaceutical and biotechnology companies have not abandoned the “one-size-fits all” approach to developing drugs, many have been bolstering their precision medicine programs through M&A.
The report provides great insight into the reasons life sciences companies are interested in precision medicine, the obstacles associated with running such programs, and how companies are going about getting a piece of the pie.
You can read the full report here. I also encourage you to download our guide, which features an overview of precision medicine and real-world examples from life sciences and healthcare.
